This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-3118v1 69/3/873    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Memon, A. A. Articles by Nexo, E. Search for Related Content PubMed PubMed Citation Articles by Memon, A. A. Articles by Nexo, E.

Positron Emission Tomography (PET) Imaging with [¹¹C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts

¹ Department of Clinical Biochemistry, ² PET Center, ³ Medical Department V, Aarhus University Hospital, Aarhus Sygehus, Norrebrogade, and ⁴ Department of Medical Microbiology and Immunology, Aarhus University, Aarhus, Denmark

Requests for reprints: Ashfaque A. Memon, Department of Clinical Biochemistry, AS, Aarhus University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark. Phone: 45-8949-2911; Fax: 45-8949-3060; E-mail: ashfaque.a.memon{at}gmail.com.

Key Words: erlotinib • PET scanning • epidermal growth factor receptor • xenografts • lung cancer

Erlotinib (Tarceva) targets the epidermal growth factor receptor (EGFR), which is commonly overexpressed in human cancers, including lung cancer. We show that erlotinib can be labeled with [¹¹C] by reacting the normethyl precursor with [¹¹C]-methyl iodide. By using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide proliferation assay, two lung cancer cell lines (A549 and NCI358) were shown to be less sensitive to erlotinib compared with the lung cancer cell line HCC827. This correlated with higher expression and activity of the EGFR in HCC827 cells as compared with the less sensitive cell lines. Micro–positron emission tomography (PET) and biodistribution of erlotinib was performed with [¹¹C]-erlotinib in nude mice bearing xenografts of A549, NCI358, and HCC827 cells. Dynamic micro-PET showed that HCC827 tumors had the highest [¹¹C]-erlotinib uptake and retained the activity significantly longer as compared with A549 and NCI358 tumors. Biodistribution of [¹¹C]-erlotinib in the xenograft models of lung cancer showed the highest accumulation in the liver. In mice carrying the sensitive cancer cells, the accumulation of [¹¹C]-erlotinib was higher in tumors than in the other organs. In contrast, the drug accumulated to a comparable extent in tumors from the less sensitive cancer cells and the other organs. Uptake of [¹¹C]-erlotinib in the tumors was 1.6%, 0.7%, and 3.7% (percentage of injected dose/g), in A549, NCI358, and HCC827 cells, respectively. We show for the first time that [¹¹C]-erlotinib identifies erlotinib-sensitive tumors. These results pave the road for studies examining the benefit of [¹¹C]-erlotinib PET in patients with lung tumors or other tumors overexpressing EGFR. [Cancer Res 2009;69(3):873–8]

This article has been cited by other articles:

				E. Mishani and A. Hagooly Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer J. Nucl. Med., August 1, 2009; 50(8): 1199 - 1202. [Abstract] [Full Text] [PDF]

				L. Ningbo, Y. Jinming, M. Xue, and S. Jian Reply: Molecular Imaging of EGFR: It's Time to Go Beyond Receptor Expression J. Nucl. Med., July 1, 2009; 50(7): 1197 - 1198. [Full Text] [PDF]

				M. A Pantaleo, M. Nannini, S. Fanti, S. Boschi, P.-L. Lollini, and G. Biasco Molecular Imaging of EGFR: It's Time to Go Beyond Receptor Expression J. Nucl. Med., July 1, 2009; 50(7): 1195 - 1196. [Full Text] [PDF]